RECRUITING Not applicable ClinicalTrials.gov

Effect of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery

Sponsor: Alexandria University • ClinicalTrials.gov ID: NCT07523438

Registry updated: 2026-09-30

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg /kg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg/kg

Interventions

high dex group (Other)
patients will receive 3 mcg/kg intranasal dexmedetomidine 45minutes before surgery
low dex group (Other)
patients will receive 2 mcg/kg intranasal dexmedetomidine 45minutes before surgery

Eligibility criteria

Inclusion Criteria: * Age: 3-6 years, both sexes * ASA physical status class I , II. Exclusion Criteria: * history of neurological and psychiatric disease * body mass index \> 20 kg m-2 * allergy to dexmedetomidine * patients on medical treatment which has any sedative effect * mentally retarded children

Conditions

Dexmedetomidine Emergence Agitation

Locations

Alexandria University — Alexandria, Egypt

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment